Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Respiratory Research|December 4, 2025
Signal regulating proteins (SIRPs) participate in sarcoidosis granuloma formation by promoting immune cell aggregationMarc A Judson, Mark W Julian, Llewellyn Foulke, et al.
Clinical Pharmacology and Therapeutics|May 9, 2018
A Randomized, First-in-Human, Healthy Volunteer Trial of sutimlimab, a Humanized Antibody for the Specific Inhibition of the Classical Complement PathwayJohann Bartko, Christian Schoergenhofer, Michael Schwameis, et al.
Transplantation|September 20, 2017
Blockade of HLA Antibody-Triggered Classical Complement Activation in Sera From Subjects Dosed With the Anti-C1s Monoclonal Antibody TNT009-Results from a Randomized First-in-Human Phase 1 TrialJakob Mühlbacher, Bernd Jilma, Markus Wahrmann, et al.
Blood Advances|March 10, 2023
SAR443809: a selective inhibitor of the complement alternative pathway, targeting complement factor BbVaishnavi Rajagopal, Nina Leksa, Ronald Gorham, et al.
The Journal of Investigative Dermatology|June 24, 2019
Specific Inhibition of the Classical Complement Pathway Prevents C3 Deposition along the Dermal-Epidermal Junction in Bullous PemphigoidPatricia Colchete Freire, Cristina Herraez Muñoz, Ulla Derhaschnig, et al.
ACR Open Rheumatology|July 16, 2024
Signal Regulatory Protein α Expression in Systemic VasculitisShubhasree Banerjee, Eileen Rose, Sandip Panicker, et al.
Blood|December 19, 2018
Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trialUlrich Jäger, Shirley D'Sa, Christian Schörgenhofer, et al.
British Journal of Pharmacology|July 2, 2010
AF-353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonistJoel R Gever, Rothschild Soto, Robert A Henningsen, et al.
Molecular Immunology|January 30, 2013
Characterization of a novel CRAC inhibitor that potently blocks human T cell activation and effector functionsGang Chen, Sandip Panicker, Kai-Yeung Lau, et al.
Advanced Therapeutics|October 10, 2022
Classical Complement Pathway Inhibition in a "Human-On-A-Chip" Model of Autoimmune Demyelinating NeuropathiesJohn W Rumsey, Case Lorance, Max Jackson, et al.
Pageof 2